Seelos Therapeutics, Inc.

Equities

SEEL

US81577F3073

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:59:48 30/05/2024 BST			5-day change	1st Jan Change
1.206 ^USD	-9.32%		-11.97%	-89.15%

05-16	Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	CI
05-14	Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	MT

Seelos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 12, 2023 at 09:06 pm

Seelos Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was USD 0.808 million. Net loss was USD 13.43 million compared to USD 14 million a year ago.

Basic loss per share from continuing operations was USD 3.6 compared to USD 3.9 a year ago.

Latest news about Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	05-15	CI
Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	05-14	MT
Seelos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Seelos Therapeutics, Inc. Announces Resignation of Daniel J. O?Connor from the Board	05-03	CI
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors	04-29	CI
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	03-19	MT
Seelos Therapeutics' ALS treatment fails in mid-stage study	03-19	RE
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)	03-19	CI
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	03-04	MT
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	03-04	MT
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement	01-26	MT
Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002	01-22	CI
Certain Warrants of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	01-12	CI
Certain Stock Options of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	01-12	CI
Certain Common Stock of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	01-12	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	12-19	MT
Seelos Therapeutics Files $250 Million Mixed Shelf	12-19	MT
Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from S&P Global BMI Index	12-18	CI
Seelos Therapeutics Insider Bought Shares Worth $100,223, According to a Recent SEC Filing	12-01	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	11-29	MT
Sector Update: Health Care	11-29	MT
Top Midday Decliners	11-29	MT
Top Premarket Decliners	11-29	MT
Seelos Therapeutics Prices Common Stock Offering	11-29	MT

Chart Seelos Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
SEELOS THERAPEUTICS, INC.	-89.15%	3.18M
VERTEX PHARMACEUTICALS INCORPORATED	+8.92%	114B
REGENERON PHARMACEUTICALS, INC.	+10.48%	105B
ARGENX SE	-1.83%	21.73B
BIONTECH SE	-6.45%	23.83B
GENMAB A/S	-10.39%	18.1B
WUXI APPTEC CO., LTD.	-42.36%	16.34B
BEIGENE, LTD.	-14.45%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+3.76%	13.75B
SAREPTA THERAPEUTICS, INC.	+28.94%	11.76B

Bio Therapeutic Drugs